{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=104", "query": { "condition": "Multiple Cancers", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 4781, "total_pages": 479, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T16:56:50.350Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05597345", "title": "Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-08-21", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05597345" }, { "nct_id": "NCT01351545", "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancies", "Inherited Disorders of Metabolism", "Inherited Abnormalities of Platelets", "Histiocytic Disorders", "Acute Myelogenous Leukemia (AML or ANLL)", "Acute Lymphoblastic Leukemia (ALL)", "Other Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases", "Other Leukemia", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma", "Multiple Myeloma/ Plasma Cell Disorder (PCD)", "Inherited Abnormalities of Erythrocyte Differentiation or Function", "Disorders of the Immune System", "Autoimmune Diseases", "Severe Aplastic Anemia" ], "interventions": [ { "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 99999, "start_date": "2011-10", "completion_date": "2041-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351545" }, { "nct_id": "NCT00091377", "title": "Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "phenoxodiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 65, "start_date": "2004-08", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091377" }, { "nct_id": "NCT00002657", "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 20, "start_date": "1995-05", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002657" }, { "nct_id": "NCT02886065", "title": "A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Hiltonol", "type": "DRUG" }, { "name": "Citarinostat", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "PVX-410", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-03-07", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 6, "location_summary": "Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02886065" }, { "nct_id": "NCT01792102", "title": "Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib and Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2013-04", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-03-05", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 2, "location_summary": "West Hollywood, California • Hackensack, New Jersey", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01792102" }, { "nct_id": "NCT07336472", "title": "A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "IBI3003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fortvita Biologics (USA)Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2026-09-30", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07336472" }, { "nct_id": "NCT00322101", "title": "Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Acute Myeloid Leukemia/Transient Myeloproliferative Disorder", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Myelodysplastic Syndromes", "de Novo Myelodysplastic Syndromes", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER", "GENETIC" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 25, "start_date": "2006-01", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 7, "location_summary": "Denver, Colorado • Altanta, Georgia • New York, New York + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Altanta", "state": "Georgia" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00322101" }, { "nct_id": "NCT01183065", "title": "Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pralatrexate With Vitamin B12 and Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2010-08", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183065" }, { "nct_id": "NCT03605719", "title": "Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pelareorep", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-10-24", "completion_date": "2022-10-10", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-11-12T16:56:50.350Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Salt Lake City, Utah", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03605719" } ] }